长期随访：全身高血压合并视网膜中央静脉阻塞相关性黄斑水肿患者接受多次抗 VEGF 治疗注射后脉络膜中央厚度变薄的变化。

Long-Term Follow-Up Changes of Central Choroidal Thickness Thinning after Repeated Anti-VEGF Therapy Injections in Patients with Central Retinal Vein Occlusion-Related Macular Edema with Systemic Hypertension.

机构信息

Department of Ophthalmology, Osaka Medical College, Takatsuki, Japan,

Department of Ophthalmology, Osaka Medical College, Takatsuki, Japan.

出版信息

Ophthalmologica. 2020;243(2):102-109. doi: 10.1159/000504754. Epub 2019 Dec 18.

DOI:10.1159/000504754

PMID:31851998

Abstract

PURPOSE

We investigated the thinning of central choroidal thickness (CCT) following intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) drugs to treat central retinal vein occlusion (CRVO)-related macular edema in patients with and without systemic hypertension (HT) to assess the influence of repeated anti-VEGF therapy and HT on the choroid in CRVO eyes.

METHODS

We conducted a retrospective study involving 27 patients with CRVO-related macular edema from January 2014 to July 2017, with follow-ups exceeding 18 months. Visual acuity (VA), central retinal thickness (CRT), and CCT were evaluated before and after initial anti-VEGF drug treatment during follow-up.

RESULTS

The mean follow-up period was 35.2 months. Seventeen (63.0%) patients had HT. At 1 month after treatment, VA had improved in 21 (77.8%) patients, and CRT had decreased in 25 (92.6%). At the final visit, 22 (81.5%) showed improved VA, 19 (70.4%) had resolved macular edema, and the CCT had gradually become thinner with additional drug injections in all the patients. Furthermore, the mean CCT in HT patients (209.0 µm) was significantly lower than in non-HT patients (256.1 µm), and the mean injections were 7.8 and 5.3, respectively (p = 0.2067).

CONCLUSION

The CCTs were thinner in eyes with HT than in eyes without HT both before and after the repeated anti-VEGF injections.

摘要

目的

我们研究了玻璃体内注射抗血管内皮生长因子（anti-VEGF）药物治疗伴有或不伴有系统性高血压（HT）的视网膜中央静脉阻塞（CRVO）相关黄斑水肿患者后中央脉络膜厚度（CCT）的变薄情况，以评估重复抗 VEGF 治疗和 HT 对 CRVO 眼脉络膜的影响。

方法

我们进行了一项回顾性研究，纳入了 2014 年 1 月至 2017 年 7 月期间的 27 例 CRVO 相关黄斑水肿患者，随访时间超过 18 个月。在随访期间，我们评估了初始抗 VEGF 药物治疗前后的视力（VA）、中心视网膜厚度（CRT）和 CCT。

结果

平均随访时间为 35.2 个月。17 例（63.0%）患者患有 HT。治疗后 1 个月，21 例（77.8%）VA 改善，25 例（92.6%）CRT 降低。在最后一次就诊时，22 例（81.5%）VA 改善，19 例（70.4%）黄斑水肿消退，所有患者随着药物注射次数的增加，CCT 逐渐变薄。此外，HT 患者的平均 CCT（209.0 µm）明显低于非 HT 患者（256.1 µm），平均注射次数分别为 7.8 和 5.3（p = 0.2067）。